CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation - PubMed (original) (raw)

Mireia Camós, Dolors Colomer, Neus Villamor, Jordi Esteve, Dolors Costa, Ana Carrió, Marta Aymerich, Josep Lluis Aguilar, Alícia Domingo, Francesc Solé, Federico Gomis, Lourdes Florensa, Emili Montserrat, Elias Campo

Affiliations

PMID: 15101047
DOI: 10.1002/gcc.20022

Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation

María Rozman et al. Genes Chromosomes Cancer. 2004 Jun.

Abstract

The t(8;16)(p11;p13) fuses the MOZ (MYST3) gene at 8p11 with CBP (CREBBP) at 16p13 and is associated with an infrequent but well-defined type of acute myeloid leukemia (AML) that has unique morphocytochemical findings (monocytoid blast morphology with erythrophagocytosis and simultaneously positive for myeloperoxidase and nonspecific esterases). RT-PCR amplification of MOZ/CBP (MYST3/CREBBP) chimera has proved difficult, with four different transcripts found in four reported cases. We studied 7 AML-t(8;16) patients, 5 with cytogenetically demonstrated t(8;16) and 2 with similar morphocytochemical and immunophenotypical characteristics. Clinically, 3 cases presented as therapy-related leukemia. Extramedullar involvement was observed at presentation in 2 patients and coagulopathy in 4. The clinicobiological findings confirmed the distinctiveness of this entity. Of note is the erythrophagocytosis in 5 of 7 cases and the immunological negativity for CD34 and CD117 and positivity for CD56. Using a new RT-PCR strategy, we were able to amplify a specific band of 212 bp in six cases in which sequence analysis confirmed the presence of the previously described MOZ/CBP fusion transcript type I. This is the largest molecularly studied AML-t(8;16) series, which demonstrates that MOZ/CBP breakpoints are usually clustered in intron 16 of MOZ and intron 2 of CBP. The newly designed single-round PCR provides a simple tool for the molecular confirmation of MOZ/CBP rearrangement.

PubMed Disclaimer

Comment in

MYST3/CREBBP (MOZ/CBP) and CREBBP/MYST3 (CBP/MOZ) transcripts in AML with t(8;16)(p11;p13).
Schmidt HH. Schmidt HH. Genes Chromosomes Cancer. 2005 Feb;42(2):207-8; author reply 209. doi: 10.1002/gcc.20112. Genes Chromosomes Cancer. 2005. PMID: 15540217 No abstract available.

Cited by

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency.
Sheridan M, Maqbool MA, Largeot A, Clayfield L, Xu J, Moncaut N, Sellers R, Whittle J, Paggetti J, Iqbal M, Aucagne R, Delva L, Baker SM, Lie-A-Ling M, Kouskoff V, Lacaud G. Sheridan M, et al. J Hematol Oncol. 2024 Oct 8;17(1):91. doi: 10.1186/s13045-024-01610-0. J Hematol Oncol. 2024. PMID: 39380002 Free PMC article.
Alzheimer's Disease-Related Epigenetic Changes: Novel Therapeutic Targets.
Paniri A, Hosseini MM, Akhavan-Niaki H. Paniri A, et al. Mol Neurobiol. 2024 Mar;61(3):1282-1317. doi: 10.1007/s12035-023-03626-y. Epub 2023 Sep 12. Mol Neurobiol. 2024. PMID: 37700216 Review.
Pantothenate and L-Carnitine Supplementation Improves Pathological Alterations in Cellular Models of KAT6A Syndrome.
Munuera-Cabeza M, Álvarez-Córdoba M, Suárez-Rivero JM, Povea-Cabello S, Villalón-García I, Talaverón-Rey M, Suárez-Carrillo A, Reche-López D, Cilleros-Holgado P, Piñero-Pérez R, Sánchez-Alcázar JA. Munuera-Cabeza M, et al. Genes (Basel). 2022 Dec 6;13(12):2300. doi: 10.3390/genes13122300. Genes (Basel). 2022. PMID: 36553567 Free PMC article.
Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer.
Douglas JK, Callahan RE, Hothem ZA, Cousineau CS, Kawak S, Thibodeau BJ, Bergeron S, Li W, Peeples CE, Wasvary HJ. Douglas JK, et al. Mol Cell Oncol. 2020 Mar 2;7(3):1716618. doi: 10.1080/23723556.2020.1716618. eCollection 2020. Mol Cell Oncol. 2020. PMID: 32391418 Free PMC article.
Five new cases of syndromic intellectual disability due to KAT6A mutations: widening the molecular and clinical spectrum.
Urreizti R, Lopez-Martin E, Martinez-Monseny A, Pujadas M, Castilla-Vallmanya L, Pérez-Jurado LA, Serrano M, Natera-de Benito D, Martínez-Delgado B, Posada-de-la-Paz M, Alonso J, Marin-Reina P, O'Callaghan M, Grinberg D, Bermejo-Sánchez E, Balcells S. Urreizti R, et al. Orphanet J Rare Dis. 2020 Feb 10;15(1):44. doi: 10.1186/s13023-020-1317-9. Orphanet J Rare Dis. 2020. PMID: 32041641 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
- Wiley
Medical
- MedlinePlus Health Information
Molecular Biology Databases
- The Weizmann Institute of Science GeneCards and MalaCards databases
Research Materials
- NCI CPTC Antibody Characterization Program

Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation - PubMed (original) (raw)